The administration of a dual CCR2/CCR5 antagonist has shown to improve obesity-associated insulin resistance and glucose intolerance via reducing macrophages and CD8+ T-cell numbers in the white adipose tissue of HFD-fed mice, indicating that blocking both CCR2 and CCR5 has potential to maintain both metabolic and immune homeostasis in obesity-induced inflammation (Huh et al., 2018). This evidence concerns the gene CCR5 and obesity disorder.